SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-130027
Filing Date
2022-12-27
Accepted
2022-12-27 07:02:31
Documents
12
Period of Report
2022-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233259d2_8k.htm   iXBRL 8-K 28929
  Complete submission text file 0001104659-22-130027.txt   201388

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20221227.xsd EX-101.SCH 3030
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20221227_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20221227_pre.xml EX-101.PRE 22593
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2233259d2_8k_htm.xml XML 3483
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 221486792
SIC: 2834 Pharmaceutical Preparations